Cao Ruijie, Wu Chensi, Lv Yalei, Xu Shuo, Li Cuizhen, Yin Fei, Li Jing
Department of Immunology and Rheumatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.
Department of Gastroenterology and Hepatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.
Oncol Lett. 2022 Dec 20;25(2):55. doi: 10.3892/ol.2022.13641. eCollection 2023 Feb.
Immune-related adverse events (irAEs) caused by immune checkpoint inhibitors (ICIs) are associated with improved treatment efficacy in certain types of cancer. In the present study, we assessed the association between irAEs and ICI efficacy. Patients with esophageal squamous cell carcinoma (ESCC) who received ICI treatment were stratified into irAEs and non-irAE groups. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were used to evaluate the therapeutic efficacy of ICIs. Of the 78 ICI-treated ESCC patients, 39 developed irAEs. The median OS and PFS for all patients were 600 and 300 days, respectively. Median OS (P<0.001) and PFS (P<0.001) times of the patients with irAEs were longer than those in the non-irAE group. In addition, the DCR of the irAE group was higher than that of the non-irAE group (P=0.006). Univariate analysis indicated that the non-irAE group was associated with a relatively shorter OS [hazard ratio (HR)=3.687, 95% CI, 1.974-6.888, P<0.001] and PFS (HR=2.967, 95% CI, 1.691-5.204, P<0.001). The multifactorial analysis demonstrated that irAE status was an independent predictor of PFS (HR=3.564, 95% CI, 1.786-7.114, P<0.001) and OS (HR=3.288, 95% CI, 1.636-6.606, P=0.001). In conclusion, the present study demonstrated that irAEs could be used to predict improved treatment efficacy in patients with ESCC who received ICI therapy.
免疫检查点抑制剂（ICI）引起的免疫相关不良事件（irAE）与某些类型癌症的治疗效果改善相关。在本研究中，我们评估了irAE与ICI疗效之间的关联。接受ICI治疗的食管鳞状细胞癌（ESCC）患者被分为irAE组和非irAE组。采用客观缓解率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）和总生存期（OS）来评估ICI的治疗效果。在78例接受ICI治疗的ESCC患者中，39例发生了irAE。所有患者的中位OS和PFS分别为600天和300天。发生irAE的患者的中位OS（P<0.001）和PFS（P<0.001）时间长于非irAE组。此外，irAE组的DCR高于非irAE组（P=0.006）。单因素分析表明，非irAE组的OS相对较短[风险比（HR）=3.687，95%CI，1.974-6.888，P<0.001]和PFS（HR=2.967，95%CI，1.691-5.204，P<0.001）。多因素分析表明，irAE状态是PFS（HR=3.564，95%CI，1.786-7.114，P<0.001）和OS（HR=3.288，95%CI，1.636-6.606，P=0.001）的独立预测因素。总之，本研究表明，irAE可用于预测接受ICI治疗的ESCC患者的治疗效果改善。
